Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 2, Therapeutic Exploratory Study)

NCT03184324 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

211

Enrollment

INDUSTRY

Sponsor class

Conditions

Erosive Gastroesophageal Reflux Disease

Interventions

DRUG: DWP14012
DRUG: Esomeprazole
DRUG: DWP14012 placebo
DRUG: Esomeprazole placebo

Sponsor

Daewoong Pharmaceutical Co. LTD.